p38 MAP Kinase Inhibitor III CAS: 581098-48-8
MF: C23H21FN4S
MW: 404.50
A cell-permeable potent, selective, and ATP competitive p38 MAP kinase inhibitor.

p38 MAP Kinase Inhibitor III (CAS 581098-48-8)

p38 MAP Kinase Inhibitor III | CAS 581098-48-8 is rated 5.0 out of 5 by 1.
  • y_2020, m_3, d_27, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_204158, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 135ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: ML3403; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]
Application: A cell-permeable potent, selective, and ATP competitive p38 MAP kinase inhibitor
CAS Number: 581098-48-8
Purity: ≥95%
Molecular Weight: 404.50
Molecular Formula: C23H21FN4S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

p38 MAP Kinase Inhibitor III is a compound that is cell-permeable and acts as a potent, selective, reversible and ATP competitive p38 MAP kinase inhibitor. p38 MAP Kinase Inhibitor III is an inhibitor of p38 α.


References

Laufer, S.A., et al. 2003. J. Med. Chem. 46, 3230.

Physical State :
Solid
Solubility :
Soluble in DMSO.
Storage :
Store at 4° C
IC50 :
p38α MAP kinase: IC50 = 0.38 µM; TNF-α release: IC50 = 0.16 µM (human PBMC); IL-1β release: IC50 = 0.039 µM (human PBMC)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
6419739
SMILES :
CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(NC(=N3)SC)C4=CC=C(C=C4)F

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

p38 MAP Kinase Inhibitor III  Product Citations

See how others have used p38 MAP Kinase Inhibitor III. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 22348531  Shi, D. et al. 2012. Journal of pineal research. 53: 154-65.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 117ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Munoz Munoz, L. et al. (PubMed 20226180) reported that the p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. -SCBT Publication Review
Date published: 2015-04-02
  • y_2020, m_3, d_27, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_204158, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 23ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.